Cargando…

Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma

Detalles Bibliográficos
Autores principales:	Zheng, Yixuan James, Lee, Albert, Pincus, Laura, Ho, Wilson, Vujic, Marin, Ortiz-Urda, Susana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991899/ https://www.ncbi.nlm.nih.gov/pubmed/29892669 http://dx.doi.org/10.1016/j.jdcr.2018.01.016

Ejemplares similares

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2014)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2015)

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox
por: Goldenberg, Alina, et al.
Publicado: (2015)

CD56-Negative Extranodal NK/T-Cell Lymphoma, Nasal Type, with Extranasal Cutaneous Involvement
por: Kim, Hee Joo, et al.
Publicado: (2015)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment
por: Feichtenschlager, Valentin, et al.
Publicado: (2023)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma
por: Ferguson, Ian, et al.
Publicado: (2019)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
por: Vujic, Igor, et al.
Publicado: (2016)

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
por: Sanlorenzo, Martina, et al.
Publicado: (2018)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
por: Cogen, Anna L., et al.
Publicado: (2018)

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
por: Zhang, Qi, et al.
Publicado: (2020)

Diagnostic confusion resulting from CD56 expression by cutaneous myeloid sarcoma
por: Ho, Thanh, et al.
Publicado: (2009)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

Amelanotic metastatic cutaneous melanoma
por: Mendes, Marcela Sena Teixeira, et al.
Publicado: (2013)

Metastatic Cutaneous Melanoma of the Gallbladder
por: Patel, Dhruvan, et al.
Publicado: (2017)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
por: Tsur, Neta, et al.
Publicado: (2019)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Cyriac, Sanju, et al.
Publicado: (2021)

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo
por: Posch, Christian, et al.
Publicado: (2016)

Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?
por: Charli-Joseph, Yann Vincent, et al.
Publicado: (2016)

CD56-positive Angioimmunoblastic T-cell Lymphoma Complicated by Chylothorax
por: Hori, Hiroki, et al.
Publicado: (2021)

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
por: Beck, Kristen M., et al.
Publicado: (2016)

AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
por: Ni, Dan, et al.
Publicado: (2019)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Ny, Lars, et al.
Publicado: (2021)

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
por: Navani, Vishal, et al.
Publicado: (2021)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome
por: Tos, Salem M., et al.
Publicado: (2022)

Enhancement of Antiviral CD8(+) T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2019)

Primary Esophageal Melanoma with Aberrant CD56 Expression: A Potential Diagnostic Pitfall
por: Katerji, Hani, et al.
Publicado: (2017)

Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab
por: Mallal, Peter, et al.
Publicado: (2021)

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
por: Läubli, Heinz, et al.
Publicado: (2015)

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report
por: Kuint, R., et al.
Publicado: (2017)

A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
por: Hakami, Osamah A, et al.
Publicado: (2019)

Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy
por: Helm, Matthew F., et al.
Publicado: (2017)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
por: Siciliano, Maria Anna, et al.
Publicado: (2020)

αβ-Double Negative CD4/CD8 (CD56) T cell (DNTs) in metastatic melanoma: basal frequency and behaviour during Ipilimumab treatment. Preliminary evaluations
por: De Tullio, Giacoma, et al.
Publicado: (2015)

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
por: Wu, Chi-Heng, et al.
Publicado: (2022)

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients
por: Posch, C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gasbrpvfp9qlct908m786fbcvv